Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

153

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	6.15M 7.12M 5.65M 5.32M 9.99M 672M 10.08M 66.96M 26.07M 330M 26.74M 26.17M 1.14B	P/E 2023	-3.09x	P/E 2024	-0.95x
Enterprise Value	59.25M 68.67M 54.47M 51.27M 96.34M 6.48B 97.15M 646M 251M 3.18B 258M 252M 11B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE
01/10/25	Carmat: Judiciary administrator has submitted request to convert receivership into liquidation to court	RE

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

CARMAT Stock OTC Markets

Stocks

CKMTF

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Latest news : CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	01/09/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	12/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Pierre Bastid CHM	Chairman	71	25/06/2024
Florent Battistella BRD	Director/Board Member	63	07/05/2021
Michael Mack BRD	Director/Board Member	79	20/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-50.96%	-54.87%	-	-	7.08M
STRYKER CORPORATION	-3.04%	-2.49%	-19.35%	+2.31%	119B
SMITH & NEPHEW PLC	0.00%	-2.54%	+4.97%	-9.92%	12.88B
GLAUKOS CORPORATION	-0.09%	+4.02%	+27.65%	+88.14%	7.49B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.33%	-2.48%	-47.45%	-72.42%	4.11B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.67%	0.00%	+14.87%	+32.36%	2.53B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.69%	+6.26%	-16.98%	-17.69%	1.75B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-0.18%	-2.92%	+0.36%	-19.39%	1.6B
L&C BIO CO.,LTD	+10.36%	+15.68%	+190.08%	+159.55%	1.4B
Average	-5.02%	+0.16%	+19.27%	+20.37%	18.85B
Weighted average by Cap.	-2.35%	-1.98%	-12.95%	+4.99%

	2023	2024
Net sales	3.84M 4.45M 3.53M 3.32M 6.24M 420M 6.29M 41.81M 16.28M 206M 16.69M 16.34M 713M	7.34M 8.51M 6.75M 6.36M 11.94M 803M 12.04M 80.02M 31.15M 394M 31.95M 31.27M 1.36B
Net income	-53.87M -62.44M -49.53M -46.62M -87.6M -5.89B -88.33M -587M -229M -2.89B -234M -229M -10.01B	-51.4M -59.57M -47.25M -44.47M -83.57M -5.62B -84.27M -560M -218M -2.76B -224M -219M -9.55B
Net Debt	49.64M 57.54M 45.63M 42.95M 80.71M 5.43B 81.39M 541M 211M 2.66B 216M 211M 9.22B	53.1M 61.55M 48.82M 45.95M 86.34M 5.81B 87.07M 579M 225M 2.85B 231M 226M 9.86B